AzTrials
AzTrials

GingivitisPhase 4NCT01751178

An Efficacy Study of Chlorhexidine Mouthwashes

A Phase 4 study testing Chlorhexidine Digluconate Mouthwash with Alcohol and Chlorhexidine Digluconate Mouthwash without Alcohol in people with Gingivitis, run by GlaxoSmithKline at 3 sites in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to compare subject gingival health after 6 weeks of twice daily use of a non-alcohol or alcohol containing mouthrinse and brushing compared to brushing only. Read more about this study

Who is it for?
Ages 18 to 64 yearsHealthy volunteers can take part
Conditions the study is for
Gingivitis
What is being tested?
Chlorhexidine Digluconate Mouthwash with Alcohol and Chlorhexidine Digluconate Mouthwash without Alcohol
Could I receive a placebo?
No, everyone receives an active treatment
How many people
324 participants
Where
3 sitesUnited Kingdom
Study dates
Oct 2012to Mar 2013
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 64 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral/ dental examination.
  • 5. a) Good oral health in the opinion of the investigator (allowing mild to moderate gingivitis to meet entry criteria).
  • A minimum of 20 permanent gradable teeth at screening. (Gradable teeth are those where restorative materials cover less than 25% of the tooth surface graded).
  • Mild to moderate gingivitis present at the screening visit in the opinion of the investigator.
  • Positive response to bleeding on brushing exercise at screening visit. e) A total of 20 bleeding sites or greater at baseline visit.

Who cannot join

  • Known or suspected intolerance or hypersensitivity to Chlorhexidine or other study materials (or closely related compounds) or any of their stated ingredients.
  • 5. a) Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the subject unlikely to fully complete the study or any that increases the risk to the subject or undermines the data validity.
  • Subjects requiring prophylactic antibiotic treatment prior to dental therapy.
  • Use of concomitant medication that, in the opinion of the investigator, might interfere with the outcome of the study or increases the risk to the subject (eg: phenytoin, calcium antagonists, cyclosporine, warfarin, antibiotics, immuno-suppressants).
  • Use of antibiotics within two weeks prior to the screening visit or throughout the study.
  • Use of any systemic medication which would have an effect on gingival conditions within 14 days of gingival examinations (eg: ibuprofen or aspirin therapy) 6. a) Have current active caries b) More than 3 pockets with 5mm or over. c) Excessive calculus present that interferes with the probing examination for Gingival Index.
Show all 9Show fewer
  • Other severe oral/ gingival conditions (e.g. Acute Necrotizing Ulcerative Gingivitis) that may compromise the study or the subjects in the opinion of the investigator or gingivitis examiner.
  • Medical conditions which may directly influence gingival bleeding. f) Restorations in a poor state of repair. g) Orthodontic appliances anterior cosmetic restorations and veneers. h) Enamel pitting/irregularities. 7. Subjects using chewing tobacco, pan, pan-masala, gutkha or other chewing tobacco products or subjects who have quit using any of those within the past six months prior to screening.
  • 8. b) An employee of any toothpaste manufacturer or their immediate family.

Trial locations and contacts

3 sites in 1 country.

United Kingdom3 sites
  • 4Front, Ellesmere Port

    Cheshire, CH65 4BW

  • Intertek - Manchester Science Park

    Manchester, M15 6SE

  • Intertek 4-Front Research - Widnes

    Widnes, Cheshire, WA8 6PG

Other trials in United Kingdom

About this study

Official title: Clinical Study to Evaluate the Efficacy of Chlorhexidine Mouthwashes

The aim of this study is to compare subject gingival health after 6 weeks of twice daily use of a non-alcohol or alcohol containing mouthrinse and brushing compared to brushing only.

Conditions
Gingivitis
Being tested
Chlorhexidine Digluconate Mouthwash with Alcohol, Chlorhexidine Digluconate Mouthwash without Alcohol
Medical subject headings
Gingivitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Chlorhexidine Digluconate Mouthwash with AlcoholDrug

    0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash

  • Chlorhexidine Digluconate Mouthwash without AlcoholDrug

    0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash

Study groups in NCT01751178
Study groupRoleWhat they receive
Mouthwash with AlcoholActive comparatorrinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash with alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
Receives: Drug: Chlorhexidine Digluconate Mouthwash with Alcohol
Mouthwash without AlcoholActive comparatorrinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash without alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
Receives: Drug: Chlorhexidine Digluconate Mouthwash without Alcohol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gingival Severity Index (GSI) Based on the Gingival Index (GI)

    Measure of gingival severity averaged across whole mouth site; each site scored 0, 1, 2, 3 based on GI and,

    1. GSI = 0 if GI is 0 or 1 (no bleeding)
    2. GSI = 1 if GI is 1 or 2 (bleeding)

    Measured: Change from baseline to 6 weeks

Secondary outcomes (3)
  1. Gingival Index

    The GI was assessed on the facial and lingual surfaces at six sites on each tooth (facial and lingual - distal papillae, margin and mesial papillae). These assessments were performed on all evaluable teeth using moderate pressure sweeping a blunt ended probe, which was engaged in approximately 1 millimetre (mm) into the gingival crevice. The scores could range from 0-3 (0=Absence of inflammation; 1=Mild Inflammation-Slight change in color slight change in texture, no bleeding on probing; 2=Moderate Inflammation -glazing, redness edema and hypertrophy, bleeding on probing; 3= Severe inflammation-marked redness and hypertrophy, tendency for spontaneous bleeding)

    Measured: Change from baseline to 6 weeks

  2. Turesky Modification of Quigley & Hein Plaque Index for Overall Plaque Scores

    Overall plaque scores were calculated taking the average over all tooth sites for a participant. The scores could range from 0-5 (0=No plaque; 1=Slight flecks of plaque at the cervical margin of the tooth; 2= A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth; 3=A band of plaque wider than 1 mm but covering less than 1/3 of the area to be graded of the crown of the tooth; 4=Plaque covering at least 1/3 but less than 2/3 of the area to be graded of the crown of the tooth; 5=Plaque covering 2/3 or more of the area to be graded of the crown of the tooth)

    Measured: Change from baseline to 6 weeks

  3. Turesky Modification of Quigley & Hein Plaque Index for Interproximal Plaque Scores

    Interproximal plaque scores were analyzed on the mesiofacial, distofacial, mesiolingual and distolingual surfaces, and calculated taking the average over all tooth sites for a participant. The scores could range from 0-5 (0=No plaque; 1=Slight flecks of plaque at the cervical margin of the tooth; 2= A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth; 3=A band of plaque wider than 1 mm but covering less than 1/3 of the area to be graded of the crown of the tooth; 4=Plaque covering at least 1/3 but less than 2/3 of the area to be graded of the crown of the tooth; 5=Plaque covering 2/3 or more of the area to be graded of the crown of the tooth)

    Measured: Change from baseline to 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2012 (estimated)
  2. Study startOct 2012
  3. Primary completionMar 2013
  4. Study completionMar 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
324 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01751178
Sponsor's protocol ID
RH01561
Status last verified
Jun 2014
First submitted
13 Dec 2012
Last updated
28 Jul 2014
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Chlorhexidine Digluconate Mouthwash with Alcohol and Chlorhexidine Digluconate Mouthwash without Alcohol in people with Gingivitis, run by GlaxoSmithKline at 3 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 Jul 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gingival Severity Index (GSI) Based on the Gingival Index (GI) (time frame: Change from baseline to 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in